Table Of Contents
1. Introduction
1.1 Market Definition & Scope
1.2 Research Assumptions & Abbreviations
1.3 Research Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022–2035
2.3 Market Size & Forecast, By Segmentation, 2022–2035
2.3.1 Market Size by Drug Type
2.3.2 Market Size by Source
2.3.3 Market Size by Application
2.3.4 Market Size by Route of Administration
2.3.5 Market Size by End Use Setting
2.4 Market Share & Bps Analysis, By Region, 2025
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1 Raw Material Suppliers
3.4.2 Manufacturers
3.4.3 Distributors/Suppliers
3.4.4 Customers/End-Users
3.5 Industry Life Cycle Assessment
3.6 Parent Market Overview
3.7 Market Risk Assessment
4. Statistical Insights & Trends Reporting
4.1 Mental Health & Disease Burden Trends (2025)
4.1.1 Global Prevalence of Depression, PTSD & Anxiety Disorders
4.1.2 Treatment-Resistant Depression Patient Population Trends
4.1.3 Substance Abuse & Addiction Disorder Incidence Patterns
4.1.4 Regional Mental Health Treatment Accessibility Trends
4.2 Psychedelic Therapy Adoption Trends (2025)
4.2.1 Psilocybin vs. Ketamine vs. MDMA Therapy Utilization Trends
4.2.2 Clinical vs. Therapeutic Center-Based Treatment Adoption
4.2.3 Personalized Mental Health Therapy Developments
4.2.4 Growth in Psychedelic-Assisted Psychotherapy Programs
4.3 Clinical Research & Drug Development Trends (2025)
4.3.1 Ongoing Clinical Trials by Drug Type & Indication
4.3.2 FDA Breakthrough Therapy & Regulatory Designation Trends
4.3.3 Academic & Research Institution Psychedelic Studies
4.3.4 Pharmaceutical Investment in Psychedelic Drug Pipelines
4.4 Healthcare Spending & Infrastructure Trends (2025)
4.4.1 Mental Healthcare Expenditure by Region
4.4.2 Investments in Psychedelic Treatment Clinics & Facilities
4.4.3 Insurance Coverage & Reimbursement Developments
4.4.4 Telehealth & Digital Mental Wellness Platform Integration Trends
4.5 Regulatory, Social Acceptance & Innovation Trends (2025)
4.5.1 Legalization & Decriminalization Developments by Country
4.5.2 Public Awareness & Social Acceptance Trends
4.5.3 Advancements in Synthetic & Next-Generation Psychedelic Compounds
4.5.4 Patent Filings & Innovation Activity in Psychedelic Therapeutics
5. Pet Wearable Market Segmental Analysis & Forecast, By Drug Type, 2022–2035, Value (USD Billion)
5.1 Introduction
5.2 Gamma Hydroxybutyric Acid
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2022–2035
5.3 Ketamine
5.4 Psilocybin
5.5 Lysergic Acid Diethylamide
5.6 MDMA
5.7 Dimethyltryptamine
5.8 Ibogaine
5.9 Mescaline
5.10 Others
6. Pet Wearable Market Segmental Analysis & Forecast, By Source, 2022–2035, Value (USD Billion)
6.1 Introduction
6.2 Naturally Dervied
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2022–2035
6.3 Synthetic
7. Pet Wearable Market Segmental Analysis & Forecast, By Application, 2022–2035, Value (USD Billion)
7.1 Introduction
7.2 Treatment Resistant Depression
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2022–2035
7.3 Major Depressive Disorder
7.4 Post Traumatic Stress Disorder
7.5 Substance and Opiate Addiction
7.6 Anxiety and Panic Disorders
7.7 Narcolepsy and Sleep Disorders
7.8 Alcohol Use Disorder
7.9 Others
8. Pet Wearable Market Segmental Analysis & Forecast, By Route of Administration, 2022–2035, Value (USD Billion)
8.1 Introduction
8.2 Oral
8.2.1 Key Trends
8.2.2 Market Size & Forecast, 2022–2035
8.3 Intranasal
8.4 Intravenous
8.5 Sublingual and Buccal
8.6 Transdermal
8.7 Others
9. Pet Wearable Market Segmental Analysis & Forecast, By End Use Setting, 2022–2035, Value (USD Billion)
9.1 Introduction
9.2 Specialized Psychedelic Clinics
9.2.1 Key Trends
9.2.2 Market Size & Forecast, 2022–2035
9.3 Hospitals
9.4 Research and Academic Institutes
9.5 Homecare Settings
10. Pet Wearable Market Segmental Analysis & Forecast, By Region, 2022–2035, Value (USD Billion)
10.1 Introduction
10.2 North America
10.2.1 Key Trends
10.2.2 Pet Wearable Market Size & Forecast, By Drug Type, 2022–2035
10.2.3 Pet Wearable Market Size & Forecast, By Source, 2022–2035
10.2.4 Pet Wearable Market Size & Forecast, By Application, 2022–2035
10.2.5 Pet Wearable Market Size & Forecast, By Route of Administration, 2022–2035
10.2.6 Pet Wearable Market Size & Forecast, By End Use Setting, 2022–2035
10.2.7 Pet Wearable Market Size & Forecast, By Country, 2022–2035
10.2.7.1 USA
10.2.7.2 Canada
10.3 Europe
10.3.1 Key Trends
10.3.2 Pet Wearable Market Size & Forecast, By Drug Type, 2022–2035
10.3.3 Pet Wearable Market Size & Forecast, By Source, 2022–2035
10.3.4 Pet Wearable Market Size & Forecast, By Application, 2022–2035
10.3.5 Pet Wearable Market Size & Forecast, By Route of Administration, 2022–2035
10.3.6 Pet Wearable Market Size & Forecast, By End Use Setting, 2022–2035
10.3.7 Pet Wearable Market Size & Forecast, By Country, 2022–2035
10.3.7.1 Germany
10.3.7.2 UK
10.3.7.3 France
10.3.7.4 Italy
10.3.7.5 Spain
10.3.7.6 Russia
10.3.7.7 Poland
10.3.7.8 Rest of Europe
10.4 Asia-Pacific
10.4.1 Key Trends
10.4.2 Pet Wearable Market Size & Forecast, By Drug Type, 2022–2035
10.4.3 Pet Wearable Market Size & Forecast, By Source, 2022–2035
10.4.4 Pet Wearable Market Size & Forecast, By Application, 2022–2035
10.4.5 Pet Wearable Market Size & Forecast, By Route of Administration, 2022–2035
10.4.6 Pet Wearable Market Size & Forecast, By End Use Setting, 2022–2035
10.4.7 Pet Wearable Market Size & Forecast, By Country, 2022–2035
10.4.7.1 China
10.4.7.2 India
10.4.7.3 Japan
10.4.7.4 South Korea
10.4.7.5 Australia
10.4.7.6 ASEAN Countries
10.4.7.7 Rest of Asia-Pacific
10.5 Latin America
10.5.1 Key Trends
10.5.2 Pet Wearable Market Size & Forecast, By Drug Type, 2022–2035
10.5.3 Pet Wearable Market Size & Forecast, By Source, 2022–2035
10.5.4 Pet Wearable Market Size & Forecast, By Application, 2022–2035
10.5.5 Pet Wearable Market Size & Forecast, By Route of Administration, 2022–2035
10.5.6 Pet Wearable Market Size & Forecast, By End Use Setting, 2022–2035
10.5.7 Pet Wearable Market Size & Forecast, By Country, 2022–2035
10.5.7.1 Brazil
10.5.7.2 Argentina
10.5.7.3 Mexico
10.5.7.4 Colombia
10.5.7.5 Rest of Latin America
10.6 Middle East & Africa
10.6.1 Key Trends
10.6.2 Pet Wearable Market Size & Forecast, By Drug Type, 2022–2035
10.6.3 Pet Wearable Market Size & Forecast, By Source, 2022–2035
10.6.4 Pet Wearable Market Size & Forecast, By Application, 2022–2035
10.6.5 Pet Wearable Market Size & Forecast, By Route of Administration, 2022–2035
10.6.6 Pet Wearable Market Size & Forecast, By End Use Setting, 2022–2035
10.6.7 Pet Wearable Market Size & Forecast, By Country, 2022–2035
10.6.7.1 UAE
10.6.7.2 Saudi Arabia
10.6.7.3 Qatar
10.6.7.4 Egypt
10.6.7.5 South Africa
10.6.7.6 Rest of Middle East & Africa
11. Competitive Landscape
11.1 Key Players' Positioning
11.2 Competitive Developments
11.2.1 Key Strategies Adopted (%), By Key Players, 2025
11.2.2 Year-Wise Strategies & Development, 2022 – 2025
11.2.3 Number Of Strategies Adopted By Key Players, 2025
11.3 Market Share Analysis, 2025
11.4 Product/Service & Application Benchmarking
11.4.1 Product/Service Specifications & Features By Key Players
11.4.2 Product/Service Heatmap By Key Players
11.4.3 Application Heatmap By Key Players
11.5 Industry Start-Up & Innovation Landscape
11.6 Key Company Profiles
11.6.1 Johnson and Johnson
11.6.1.1 Company Overview & Snapshot
11.6.1.2 Product/Service Portfolio
11.6.1.3 Key Company Financials
11.6.1.4 SWOT Analysis
11.6.2 Jazz Pharmaceuticals plc
11.6.3 COMPASS Pathways plc
11.6.4 MindMed Inc.
11.6.5 Cybin Inc.
11.6.6 Atai Life Sciences N.V.
11.6.7 GH Research PLC
11.6.8 Seelos Therapeutics Inc.
11.6.9 Beckley Psytech Ltd.
11.6.10 Field Trip Health and Wellness Ltd.
11.6.11 Numinus Wellness Inc.
11.6.12 Mydecine Innovations Group Inc.
11.6.13 Small Pharma Inc.
11.6.14 Awakn Life Sciences Corp.
11.6.15 Filament Health Corp.
11.6.16 Tryp Therapeutics Inc.
11.6.17 Psyence Group Inc.
11.6.18 Entheon Biomedical Corp.
11.6.19 Delic Holdings Corp.
11.6.20 PharmAla Biotech Holdings Inc.
12. Analyst Recommendations
12.1 SNS Insider Opportunity Map
12.2 Industry Low-Hanging Fruit Assessment
12.3 Market Entry & Growth Strategy
12.4 Analyst Viewpoint & Suggestions on Market Growth
13. Assumptions
14. Disclaimer
15. Appendix
15.1 List of Tables
15.2 List of Figures
Frequently Asked Questions
Ans: The Psychedelic Drugs Market is expected to grow at a CAGR of 13.68% from 2026 to 2035.
Ans: The Psychedelic Drugs Market was valued at USD 4.13 billion in 2025.
Ans: The surging global burden of mental illness and the documented failure of conventional psychiatric treatments for a large patient population, combined with expanding clinical trial evidence, evolving regulatory pathways, and growing institutional investment in psychedelic assisted therapy platforms.
Ans: The Ketamine segment dominated the Psychedelic Drugs Market in 2025, accounting for approximately 42% of total market revenue, driven by its FDA approved status and the rapid expansion of ketamine infusion clinic networks globally.
Ans: Research and Academic Institutes are expected to grow at the fastest CAGR from 2026 to 2035, driven by the expanding global pipeline of psychedelic clinical trials and growing government and institutional funding for psychedelic medicine research programs.
Get in Touch
